High risk of failing eradication of Helicobacter pylori in patients with diabetes: A meta-analysis

Diabetes Research and Clinical Practice

Volumn 106, Issue 1, 2014, Pages 81-87

  Horikawa, Chika ^a,b,c   Kodama, Saroru ^b,d   Fujihara, Kazuya ^b,c   Hirasawa, Reiko ^b   Yachi, Yoko ^b,e   Suzuki, Akiko ^b   Hanyu, Osamu ^b   Shimano, Hitoshi ^c   Sone, Hirohito ^b  

^a UNIVERSITY OF NIIGATA PREFECTURE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e YAMANASHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Diabetes; Eradication; Helicobacter pylori; Meta analysis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ARTICLE; BIOSIS; CANCER PREVENTION; DATA EXTRACTION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EMBASE; ENTEROPATHY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS (TOPIC); RISK ASSESSMENT; SCISEARCH; STOMACH CANCER; DRUG EFFECTS; HELICOBACTER INFECTIONS; META ANALYSIS; MICROBIOLOGY; RISK FACTOR; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; DIABETES MELLITUS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RISK FACTORS; TREATMENT FAILURE;

EID: 84908031223     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.07.009     Document Type: Article

References (29)

1. Chey W.D., Wong B.C. Practice Parameters Committee of the American College of Gastroenterology American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102(8):1808-1825.
2. Fuccio L., Zagari R.M., Eusebi L.H., Laterza L., Cennamo V., Ceroni L., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009, 151(2):121-128.
3. Ford A.C., Delaney B.C., Forman D., Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004, 99(9):1833-1855.
4. Zhou X., Zhang C., Wu J., Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract 2013, 99(2):200-208.
5. Fine M.J., Smith M.A., Carson C.A., Mutha S.S., Sankey S.S., Weissfeld L.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. J Am Med Assoc 1996, 2(275):134-141.
6. Shah B.R., Hux J.E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003, 26(2):510-513.
7. The European Helicobacter Pylori Study Group (EHPSG) Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997, 41(1):8-13.
8. Peura D.A. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997, 113(Suppl. 6):S4-S8.
9. Rokkas T., Sechopoulos P., Robotis I., Margantinis G., Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009, 104(1):21-25.
10. Kobayashi I., Murakami K., Kato M., Kato S., Azuma T., Takahashi S., et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007, 45(2):4006-4010.
11. Wells GA, Shea B, O'Connell D, J. Peterson, V. Welch, M. Losos, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from [accessed 24.08.13]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
12. Romano M., Cuomo A. Eradication of Helicobacter pylori: a clinical update. MedGenMed 2004, 6(1):19.
13. Haldane J.B.S. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1955, 20(4):309-311.
14. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
15. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315(7109):629-634.
16. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53(11):1119-1129.
17. Ravera M., Bahenda S., Owor R., Visonà R. Helicobacter pylori infection in diabetic patients with dyspepsia in Uganda. Dig Liver Dis 2001, 33(4):390-391.
18. Sargýn M., Uygur-Bayramicli O., Sargýn H., Orbay E., Yavuzer D., Yayla A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003, 9(5):1126-1128.
19. Demir M., Gokturk H.S., Ozturk N.A., Arslan H., Serin E., Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009, 102(11):1116-1120.
20. Demir M., Gokturk H.S., Ozturk N.A., Serin E., Yilmaz U. Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. Am J Med Sci 2009, 338(6):459-464.
21. Demir M., Göktürk S., Oztürk N.A., Serin E., Yilmaz U. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion 2010, 82(1):47-53.
22. Byun Y.H., Jo Y.J., Kim S.C., Lee J.S., Shin W.Y., Park Y.S., et al. Clinical factors that predicts successful eradication of Helicobacter pylori. Korean J Gastroenterol 2010, 48(3):172-179.
23. Candelli M., Rigante D., Marietti G., Nista E.C., Crea F., Schiavino A., et al. Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. J Pediatr Gastroenterol Nutr 2004, 38(4):422-425.
24. Gasbarrini A., Ojetti V., Pitocco D., Franceschi F., Candelli M., Torre E.S., et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999, 11(7):713-716.
25. Guyatt G.H., Oxman A.D., Kunz R., Vist G.E., Falck-Ytter Y., Schünemann H.J., et al. What is quality of evidence and why is it important to clinicians?. Br Med J 2008, 336(7651):995-998.
26. Gwilt P.R., Nahhas R.R., Tracewell W.G. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991, 20(6):477-490.
27. Groop L.C., Luzi L., De Fronzo R.A., Melander A. Hyperglycemia and absorption of sulfonylurea drugs. Lancet 1989, 2(8655):129-130.
28. Kong M.F., Macdonald I.A., Tattersall R.B. Gastric emptying in diabetes. Diabet Med 1996, 13(2):112-119.
29. Marhoffer W., Stein M., Maeser E., Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992, 15(2):256-260.